Compare SN & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SN | IONS |
|---|---|---|
| Founded | 1993 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9B | 13.5B |
| IPO Year | 2023 | 1996 |
| Metric | SN | IONS |
|---|---|---|
| Price | $124.12 | $84.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 22 |
| Target Price | ★ $132.88 | $84.09 |
| AVG Volume (30 Days) | 1.5M | ★ 1.7M |
| Earning Date | 01-01-0001 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.70 |
| Revenue | N/A | N/A |
| Revenue This Year | $15.19 | $29.86 |
| Revenue Next Year | $10.81 | $0.53 |
| P/E Ratio | ★ $25.86 | $118.79 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $60.50 | $23.95 |
| 52 Week High | $133.99 | $86.74 |
| Indicator | SN | IONS |
|---|---|---|
| Relative Strength Index (RSI) | 52.09 | 57.72 |
| Support Level | $111.44 | $75.66 |
| Resistance Level | $128.85 | $86.45 |
| Average True Range (ATR) | 6.33 | 2.59 |
| MACD | 0.32 | -0.12 |
| Stochastic Oscillator | 53.80 | 69.40 |
SharkNinja Inc is a product design and technology company that creates 5-star-rated lifestyle solutions through inventive products for consumers around the world. Its product categories include Cleaning, Cooking, Food Preparation, Home Environment and Beauty products. It sells vacuum cleaners, cooking pots, fryers, hair dryers, etc. The SharkNinja Group is expected to carry on the design, production, marketing, and distribution of the Shark and Ninja brands of small household appliances in North America, Europe and other selected international markets (excluding the Asia Pacific Region and Greater China). Currently, the majority of the revenue is derived from the U.S. market.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.